What a way to start the week. The markets are green right now and even ahead of all of the expected financial meetings this week, sentiment is high. That’s true too for the companies we talked about this morning. So let’s dive in and get everyone caught up to speed.
ParcelPal Technology Inc. (PKG.CN) (PTNYF) Jumps On Integration News
ParcelPal Technology Inc. (PKG.CN) (PTNYF) has been on the move for most of the month and the recent jump comes on the heels of this penny stock announcing integration on the Shopify platform. If you’re wondering, this is the same Shopify that trades publicly at OVER $300 a share!
Now the deal was first scooped by Benzinga and was later confirmed when ParcelPal formally announced the deal later in morning. Businesses of any kind, notably cannabis merchants will be able to integrate their Shopify eCommerce store nearly instantly to ParcelPal’s ecosystem.
These merchants will enable their customers to tap into ParcelPal’s network and have their products delivered in an hour or less. ParcelPal has begun this process with Choom and Kiaro. You can read more about the ParcelPal/Shopify News Here. Since June 3, ParcelPal is up by more than 35% and we, for one, will continue to bring more updates as we find them.
GT Biopharma, Inc. (GTBP) Consolidation Could Lead To More Excitement
GT Biopharma, Inc. (GTBP) continues to pick up the pace. Since we initiated coverage on the company, we’ve watch GTBP climb as much as 30% and as of today, it’s still up by roughly 12.5% in just over a week. We have seen a bit of consolidation to start this week but that could open the door to more excitement in June. The big focus for GTBP onlookers has been on its immunotherapy portfolio.
The bottom line here is that big money is pouring into cancer-focused companies specifically. The fact that as we write this, Pfizer is in the middle of an $11 billion dollar deal to buy a cancer therapy company should be even more proof of this focus.
To date, GT Biopharma has completed one dose escalation Phase I-II expansion clinical trial, and one fixed dose Phase I-II expansion clinical trial, which collectively enrolled a combined 43 patients. On the surface, the Phase I-II expansion clinical trial demonstrated greater than 50% of Evaluable patients receiving 60 mg/kg dose had a positive clinical response.
Two patients exhibited a Complete Remission with one patient currently disease-free at 50 months post-treatment. Additionally, five patients exhibited Stable Disease, cancers that are neither increasing nor decreasing in severity, with the longest response lasting 12 months post-treatment. In addition to this, the company’s therapy has also shown that it could target HIV infected cells in the University of Minnesota’s preclinical testing. Not only that but in specific tests, data showed that HIV-infected targets that express the HIV envelope on their surface could be eliminated. We’ve put together a full report on GTBP so click here for more info.
Liberty Defense Holdings, Ltd. (SCAN.V) Surges On German Deal
We brought this back to the attention of our members earlier last week and since then things have been quite exciting to say the least. Here’s why: Liberty Defense was trading at CAD$0.69 and today we’ve witnessed a big boom to highs of $0.85 after making another big MOU announcement. What was the news? Liberty Defense (SCAN.V) will be collaborating with FC Bayern München to beta test HEXWAVE. You can read the whole PR here.
This is what Bill Riker, CEO of Liberty Defense, said about this deal, “The reception to our HEXWAVE product has been fantastic and we are excited about working alongside FC Bayern Munich, a team that is a household name in both Europe and North America. Our ability to deploy in both indoor and outdoor settings, with covert and overt applications, sets us apart and has also been driving increasing interest from the market.”
Blackberry Stock Price Corrects 23% In A Month, A Value Buy?
There was a time when BlackBerry Limited (BB) used to be one of the leaders of the telecommunication industry by virtue of its smartphones. However, the company’s glory days are well in the past and the stock declined by more than 15% recently after it released its results for Q1 2019. The stock is now trading less than $8 but at the same time, it is important to note that the company has managed to deliver as far as its top-line figures are concerned.
Poor Earnings Lower Blackberry Stock Price
The software and services division is now the company’s most important division. It has emerged as the biggest revenue generator for the Canadian company. Overall sales for Blackberry rose 16% year over year in the latest reported quarter.
However, in the software and services, it was a far more pleasing picture. Its GAAP revenues rose 27% year over year. The company seems to be on the right track in terms of its plan to turn around. But the market doesn’t seem to take a fancy to it. The reasons behind this might have something to do with allegations made by certain parties.
They say that the company uses non-GAAP methods to report earnings. If there is any kind of accounting cloud over a company, growth may be far away.
Where Does This Leave Blackberry Stock Price?
However, Blackberry has been quick to defend itself against these allegations. Financial disclosures of the company are fully SEC compliant. It remains to be seen whether the SEC takes an interest in the matter.
This problem has been the biggest reason behind the underperformance of Blackberry stock price. That’s despite the company’s decent performance. The acquisition of machine learning company Cyclane is also a positive development. But it remains to be seen how it affects Blackberry’s future growth.
Uber Technologies (UBER) Stock Price Hits $45 Mark Again; Are Delivery Stocks Set To Fly?
Uber Technologies (UBER) stock price hit its IPO level of $45 again. Since its IPO, this becomes the fourth time that the company has hit its $45 mark. Each time it has been a real challenge for the company to rise above the IPO price.
Uber has made its name through its market dominance however it’s growth continues to be slow-paced and also has continuous losses, making Uber less attractive to many. However, the thing that Uber has done is bring more attention to the on-demand and delivery stock arena.
Special Delivery: Small-Cap Delivery Stocks Are Gaining Ground In Cannabis
Driven Deliveries Inc. (OTC: DRVD) is one of the only publicly traded cannabis delivery service operating in the United States. Now that’s what we call first-mover advantage. Driven Deliveries provides on-demand marijuana delivery in select cities where allowed by law. The service provides the legal cannabis consumer the ability to purchase and receive their marijuana in a fast and convenient manner.
>>Read More>> Two Massive Growth Industries, One Choice for Investors
Consumers are growing increasingly lazy with most of all purchases from retail to food shopping being done online. And now you can add weed to that list. Driven Deliveries (OTC: DRVD) is quickly gaining steam in legal US markets as the new delivery option for customers is resulting in increased revenue and transactions for dispensaries.
Food delivery apps and services such as GrubHub and Uber Eats have already expanded revenue generated in the food-service industry by 22% or more. Consumers love getting what they want without having to leave their house to get it, plain and simple.
In Spite Of Being A Broken IPO, Still Worth An Investment
Cannabis is just one small niche expanding into the on-demand technology market. Uber has always managed to capture the headlines. This week it did that by launching itself in the sixth German city, Hamburg. The company further has plans to acquire Postmates which gives UberEats a heavy competition provided the price is right.
McDonald’s exclusivity with Uber also came to an end this year with the former getting into a contract with DoorDash. The company is set to report its financial results for Q2 on August 8. Uber had given accounts of its earlier performance through the prospectus issued during the IPO.
UBER stock price has been trading at $40 range since June. But, the figure is likely to change in the coming future for better. Uber has been able to disrupt various markets like those of food delivery, personal mobility, and freight logistics. In Q1 results, the company had reported 93 million monthly active platform consumers.
The revenue of the company has been on a slow rise especially on a net basis. The company sends a major portion of the money received to its drivers to keep them encouraged and active. This is a move that is not going away anytime soon. The deep deficits could also prove to be advantageous for the company.
Even though Uber looks like a broken IPO, it still leads in its industry. The concerns with the valuation persist still for good reasons. Uber continues to ride at a market cap which is five times the current year’s revenue. But, one would have to wait till 2025 to see a positive earning in the growing market.
Stock Price Friday Update – July 19, 2019
ROKU Stock Price Hits Another Life Time High: Good News For Tech Stocks?
In 2019 alone, ROKU stock has risen by as much as 271% as the company continued to add new customers and boosted revenues from advertising. However, could the latest surge be a signal for the next bull market in tech?
3 Biotech Stocks To Watch After Big News This Month
Here is a look at 3 biotechnology stocks that proved to be winners recently.
IPO News: Medallia Goes Public On Friday, July 19
Over 14 million shares of the company will be available to be traded at $16 to $18 per share on NYSE. And of course, investors will be watching MDAL stock price closely. Bank of America Merrill Lynch, Citigroup, and Wells Fargo Securities will oversee the IPO.
Search Stock Price (StockPrice.com)
Sponsored Content1 month ago
Special Delivery! On-Demand Tech Companies Hit Billion-Dollar Valuations; Here’s How Investors Can Capitalize In The Market
Featured4 months ago
Multi-Trillion Dollar Industry Providing Massive Opportunity in 2019 & Beyond
Cannabis3 months ago
Two Massive Growth Industries, One Choice for Investors
Biotechnology1 month ago
Big Investments Are Signaling The Green Light For A ‘Hot Market’ With Cancer-Fighting Stocks
Featured1 month ago
This New Technology Could Transform A Multi-Billion-Dollar Industry!
Cannabis2 months ago
A New Cannabis Trend That The Market Should Take Immediate Notice Of Is Here!
Biotechnology2 weeks ago
The Future Of Drug Delivery Has Biotech Investors Focusing On One Small Company
Featured3 months ago
Opportunity Ahead for This Healthcare Stock